Stem Cell Clinic

Authorized MFIII (MF3) – Cell Placenta Therapy For Anti-Aging

By Uncategorized

You no longer have to be Rich and famous to experience the Profound Healing effects and Intense Revitalizing and Anti-Aging benefits of MFIII (MF3) Live Cell Therapy - the best anti-aging product available in the world! Thanks to Swiss innovation and Technology, this amazing anti-aging product is now available for the first time in 70 years, and some refer to this scientific breakthrough in anti-aging and looking young as the Stem Cell in a Capsule.

Whether you are sick or experiencing chronic fatigue or just seeking the best Anti-aging and Skin Beauty supplement, everyone will benefit from the rejuvenation and regeneration of MFIII of Switzerland Live Cell Therapy. Best of all, it's acompletely Natural and Safe anti-aging solution, facilitatating and enhancing the body's ability to heal itself naturally, free from any side effects.

At last, you can feel younger, reduce cellular aging and feel full of vitality, energy, and dynamism in around 3-6 weeks with MFIII Switzerland hi-tech oral supplement formulation. MF III ( MF3) Sheep and Vegetal Placenta helps to awaken dormant cells inside the body, thereby enhancing the expression and function of existing cells, revitalizing and regenerating old and malfunctioning cells. This amazing anti-aging supplement offers what vitamins, minerals, hormones, chemicals and other typical treatments can't to worn out cells. It facilitates the processes and actual requirements for cellular functioning, mandatory for aged, hurt or sick organs and tissues to fix and regenerate, therefore providing amazing age-defying, health beauty benefits at the very same time.

Cell Treatment (or Live Cell Therapy) was first invented in an injectible form by Swiss surgeon Dr Paul Niehans in 1931. As you'll soon learn: Cell Therapy is essentially the forerunner of the better-known Human Stem Cell Therapy, which was invented in the 1960s based mostly on the principle of Cell Therapy.

Due to their intense health and beauty benefits but exceedingly high cost, Cell Therapy injections have for a while been a celebrity secret in protecting a young appearance and supporting critical health problems. Pope Pius XII was so happy with the treatment that he inducted Dr Paul Niehans, the deviser of Cell Therapy, into the Papal Academy of Science, making him the successor to the late Sir Alexander Fleming, the discoverer of penicillin.

Many celebrities, presidents and members of the Swiss Soccer World Cup team have benefited from Cell Therapy. President Eisenhower, Prime Minister Winston Churchill, and French General De Gaulle received it to maintain their powers of concentration and their physical endurance. Adenauer credited live cell therapy with giving him the energy to guide the Republic of Germany though he was more than ninety years old.

Charlie Chaplin claimed it enabled him to marry again and father kids after age seventy. Exclusive hospitals for the wealthy & famous in Switzerland have administered the Anti-Aging Cell Therapy to both western and oriental celebs, improving and lengthening their vigor and conserving their young appearance and capabilities.

Actress of "Law & Order"

"There is NO compromise for quality and effectivenes. I won't settle for anything else"

European Model

Originally posted here:
Authorized MFIII (MF3) - Cell Placenta Therapy For Anti-Aging

UCSF Stem Cell Center |

By Stell Cell Research

Welcome to the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF, one of the largest and most comprehensive programs of its kind in the United States.

In some 125 labs, scientists are carrying out studies, in cell culture and animals, aimed at understanding and developing treatment strategies for such conditions as heart disease, diabetes, epilepsy, multiple sclerosis, Parkinsons disease, Lou Gehrigs disease, spinal cord injury and cancer.

While the scientific foundation for the field is still being laid, UCSF scientists are beginning to move their work toward human clinical trials. A team of pediatric specialists and neurosurgeons is carrying out the second brain stem cell clinical trial ever conducted in the United States, focusing on a rare disease, inherited in boys, known as Pelizaeus-Merzbacher disease.

Others are working to develop strategies for treating diabetes, brain tumors, liver disease and epilepsy. The approach for treating epilepsy potentially also could be used to treat Parkinsons disease, as well as the pain and spasticity that follow brain and spinal cord injury.

The center is structured along seven research pipelines aimed at driving discoveries from the lab bench to the patient. Each pipeline focuses on a different organ system, including the blood, pancreas, liver, heart, reproductive organs, nervous system, musculoskeletal tissues and skin. And each of these pipelines is overseen by two leaders of international standing one representing the basic sciences and one representing clinical research. This approach has proven successful in the private sector for driving the development of new therapies.

The center, like all of UCSF, fosters a highly collaborative culture, encouraging a cross-pollination of ideas among scientists of different disciplines and years of experience. Researchers studying pancreatic beta cells damaged in diabetes collaborate with those who study nervous system diseases because stem cells undergo similar molecular signaling on the way to becoming both cell types. The opportunity to work in this culture has drawn some of the countrys premier young scientists to the center.

While the focus of the science is the future, UCSFs history in the field dates back to 1981, when Gail Martin, PhD, co-discovered embryonic stem cells in mice and coined the term embryonic stem cell. Two decades later, UCSFs Roger Pedersen, PhD, developed two of the first human embryonic stem cell lines, following the groundbreaking discovery by University of Wisconsins James Thomson, PhD, of a way to derive the cells.

Today, the Universitys faculty includes Shinya Yamanaka, MD, PhD, of the UCSF-affiliated J. David Gladstone Institutes and Kyoto University. His discovery in 2006 of a way to reprogram ordinary skin cells back to an embryonic-like state has given hope that someday these cells might be used in regenerative medicine.

Yamanakas seminal finding highlights the unexpected and dramatic discoveries that can characterize scientific research. In labs throughout UCSF and beyond, the goal is to move such findings into patients.

The rest is here:
UCSF Stem Cell Center |

MAYO CLINIC RADIO

By Stem Cell Clinic

Posted by Dana Sparks (@danasparks) Fri, Nov 7 at 1:17pm EST

MAYO CLINIC RADIO

On the next Mayo Clinic Radio, Saturday, November 8 at 9 a.m. CT,well discuss the latest news from the Mayo Clinic Cardiology + Structural Heart Disease: Innovation Summit 2014. Replacing or repairing someone's heart valve through a blood vessel is a modern-day marvel. We'll find out how they do it. Plus, regenerating damaged heart tissue is a new frontier in cardiac care. Repair, replace and regenerate how the newest innovations can save your heart. ExpertsCharles Bruce, M.D., and Rakesh Suri, M.D.,will be with us ... hope you join us, too!

Myth or Fact: Stem cell therapy for heart disease is analternative to bypass surgery and/or stents.

Follow#MayoClinicRadioand tweet your questions.

To listen to the program on Saturday, clickhere.

Mayo Clinic Radio is available oniHeart Radio.

Listentothis weeks Medical News Headlines: News Segment November 8, 2014(right click MP3)

Mayo Clinic Radiois a weeklyone-hour radio program highlighting health and medical informationfrom Mayo Clinic.The showis tapedfor rebroadcast by some affiliates.

Original post:
MAYO CLINIC RADIO

Humans' big brains might be due in part to newly identified protein

By Stem Cell Medicine

PUBLIC RELEASE DATE:

12-Nov-2014

Contact: Scott Maier scott.maier@ucsf.edu 415-502-6397 University of California - San Francisco @ucsf

A protein that may partly explain why human brains are larger than those of other animals has been identified by scientists from two stem-cell labs at UC San Francisco, in research published in the November 13, 2014 issue of Nature.

Key experiments by the UCSF researchers revealed that the protein, called PDGFD, is made in growing brains of humans, but not in mice, and appears necessary for normal proliferation of human brain stem cells growing in a lab dish.

The scientists made their discovery as part of research in which they identified genes that are activated to make specific proteins in crucial stem cells in the brain known as radial glial cells. The discovery stems from a collaboration between the laboratories of leading radial glial cell scientist Arnold Kriegstein MD, PhD, director of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF, and Michael Oldham, PhD, who recently made a rapid career leap from graduate student to principal investigator and Sandler Fellow at UCSF.

Radial glial cells make the neurons in the growing brain, including the neurons in the cerebral cortex, the seat of higher brain functions. The cerebral cortex varies in size 10,000-fold among mammals. Changes in the timing, location and degree of cell division and nerve cell generation by radial glial cells can dramatically alter the shape and function of the cortex.

The UCSF team discovered that PDGFD is secreted by human radial glial cells and acts on radial glial cells as well as other progenitor cells in the developing brain.

"To the best of our knowledge this is the first example of any signaling pathway affecting the proliferation of radial glial cells whose activity has changed during mammalian evolution," Oldham said. "We think that the expression of PDGFD in this signaling pathway is likely to be part of the reason the human brain is so much bigger that the mouse brain."

Although the UCSF research team found that the majority of genes that are active in radial glial cells are the same in humans and mice, they identified 18 genes that are active in human but not mouse radial glial cells during development of the cerebral cortex.

Go here to see the original:
Humans' big brains might be due in part to newly identified protein

How adult fly testes keep from changing into ovaries

By Stem Cell Medical Center

8 hours ago

New research in flies shows how cells in adult reproductive organs maintain their sexual identity. The study, publishing online on November 13 in the Cell Press journal Developmental Cell, also identified a mutation that can switch the cells' sexual identity. The findings could lead to new insights on how to alter cells for therapeutic purposes.

Sperm and eggs are made from germ cells, but instructions from their neighboring support cellscalled somatic cellsare also essential for their development. By studying the formation of sperm in fruit flies, which is remarkably similar to the process that occurs in people, investigators serendipitously found a mutation that gave testes a very unusual appearance. "Rather than becoming sperm, germ cells were stuck at an early stage, and they were surrounded by support cells that looked suspiciously like those belonging in an ovary," says senior author Dr. Erika Matunis of The Johns Hopkins School of Medicine. Her research team found that the mutation blocked the function of a specific gene in the stem cells that becomes support cells in the testis, causing the fruit flies to change from a male to a female identity.

The research is the first to show that adult stem cells actively maintain their sexual identity. The mutation the investigators found causes the stem cells in males to switch their sexual identities and start making support cells that belong in the ovary. This ultimately derails the production of sperm. "The molecules that govern this process are highly conserved, which suggests that similar mechanisms could operate in human testes," says Matunis.

The changes seen in this study are an example of transdifferentiation, or the conversion from one cell type to another. The topic is of considerable interest because promoting transdifferentiation in a directed manner may be useful for regenerating damaged organs or tissues. Doing so will require a thorough understanding of how cell fate conversions are regulated. "We are excited to have a powerful genetic system for studying transdifferentiation of stem cells at the mechanistic level," says Matunis. The research might also provide insights into how cells transform from a normal state to a cancerous one.

Explore further: Surprise: Lost stem cells naturally replaced by non-stem cells, fly research suggests

More information: Developmental Cell, Ma et al.: "The Jak-STAT target Chinmo prevents sex transformation of adult stem cells in the Drosophila testis niche" http://www.cell.com/developmental-cel 1534-5807(14)00628-5

Journal reference: Developmental Cell

Provided by Cell Press

Johns Hopkins researchers have discovered an unexpected phenomenon in the organs that produce sperm in fruit flies: When a certain kind of stem cell is killed off experimentally, another group of non-stem cells can come out ...

Read the original here:
How adult fly testes keep from changing into ovaries

Tumor suppressor also inhibits key property of stem cells, Stanford researchers say

By Uncategorized

PUBLIC RELEASE DATE:

13-Nov-2014

Contact: Krista Conger kristac@stanford.edu 650-725-5371 Stanford University Medical Center @sumedicine

A protein that plays a critical role in preventing the development of many types of human cancers has been shown also to inhibit a vital stem cell property called pluripotency, according to a study by researchers at the Stanford University School of Medicine.

Blocking expression of the protein, called retinoblastoma, in mouse cells allowed the researchers to more easily transform them into what are known as induced pluripotent stem cells, or iPS cells. Pluripotent is a term used to describe a cell that is similar to an embryonic stem cell and can become any tissue in the body.

The study provides a direct and unexpected molecular link between cancer and stem cell science through retinoblastoma, or Rb, one of the best known of a class of proteins called tumor suppressors. Although Rb has long been known to control the rate of cell division, the researchers found that it also directly binds and inhibits the expression of genes involved in pluripotency.

"We were very surprised to see that retinoblastoma directly connects control of the cell cycle with pluripotency," said Julien Sage, PhD, associate professor of pediatrics and of genetics. "This is a completely new idea as to how retinoblastoma functions. It physically prevents the reacquisition of stem cellness and pluripotency by inhibiting gene expression."

Marius Wernig, MD, associate professor of pathology, said, "The loss of Rb appears to directly change a cell's identity. Without the protein, the cell is much more developmentally fluid and is easier to reprogram into an iPS cell."

Wernig and Sage, both members of the Stanford Cancer Institute, share senior authorship of the study, which will be published online Nov. 13 in Cell Stem Cell. Postdoctoral scholar Michael Kareta, PhD, is the lead author.

Tumor Suppressor

View post:
Tumor suppressor also inhibits key property of stem cells, Stanford researchers say

UCLA Researchers Identify Unique Protein Key to the Development of Blood Stem Cells

By Uncategorized

Contact Information

Available for logged-in reporters only

Newswise Led by Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research member Dr. Hanna Mikkola, UCLA scientists have discovered a unique protein that is integral to the self-renewal of hematopoietic stem cells (HSCs) during human development.

This discovery lays the groundwork for researchers to generate HSCs in the lab (in vitro) that better mirror those that develop in their natural environment (in vivo). This could lead to improved therapies for blood-related diseases and cancers by enabling the creation of patient-specific blood stem cells for transplantation.

The findings are reported online November 13, 2014, ahead of print in the journal Cell Stem Cell.

The research community has long sought to harness the promise of pluripotent stem cells (PSCs) to overcome a significant roadblock in making cell-based therapies blood and immune diseases more broadly available, which has been hampered by the inability to generate and expand human HSCs in culture. HSCs are the blood forming cells that serve as the critical link between PSCs and fully differentiated cells of the blood system. The ability of HSCs to self-renew (replicate themselves) and differentiate to all blood cell types, is determined in part by the environment that the stem cell came from, called the niche.

In the five-year study, Mikkola and Drs. Sacha Prashad and Vincenzo Calvanese, members of Mikkolas lab and lead authors of the study, investigated a unique HSC surface protein called GPI-80. They found that it was produced by a specific subpopulation of human fetal hematopoietic cells that were the only group that could self-renew and differentiate into various blood cell types. They also found that this subpopulation of hematopoietic cells was the sole population able to permanently integrate into and thrive within the blood system of a recipient mouse.

Mikkola and colleagues further discovered that GPI-80 identifies HSCs during multiple phases of human HSC development and migration. These include the early first trimester of fetal development when newly generated HSCs can be found in the placenta, and the second trimester when HSCs are actively replicating in the fetal liver and the fetal bone marrow.

We found that whatever HSC niche we investigated, we could use GPI-80 as the best determinant to find the stem cell as it was being generated or colonized different hematopoietic tissues, said Mikkola, associate professor of molecular, cell and development biology at UCLA and also a member of the Jonsson Comprehensive Cancer Center. Moreover, loss of GPI-80 caused the stem cells to differentiate. This essentially tells us that GPI-80 must be present to make HSCs. We now have a very unique marker for investigating how human hematopoietic cells develop, migrate and function.

Mikkolas team is actively exploring different stages of human HSC development and PSC differentiation based on the GPI-80 marker, and comparing how blood stem cells are being generated in vitro and in vivo. This paves the way for scientists to redirect PSCs into patient-specific HSCs for transplantation into the patient without the need to find a suitable donor.

Read the rest here:
UCLA Researchers Identify Unique Protein Key to the Development of Blood Stem Cells

Researchers Discover Breakthrough Stem Cell Treatment For Parkinson's Disease

By Stem Cell Treatment

By C. Rajan, contributing writer

Researchers at Lund University in Sweden have made a major breakthrough in Parkinson's disease treatment by developing stem cell-derived brain cells that can replace the cells lost due to the disease, thus paving the way for the first stem cell transplant treatment for Parkinsons patients.

Parkinson's disease, which affects about 10 million people worldwide, is a degenerative nervous system condition which causes tremors, muscle weakness, stiffness, and loss in mobility. Parkinson's is caused by loss of dopamine-producing neurons in the brain. Dopamine is an essential neurotransmitter that is required for regulating movement and emotions.

In this study, for the first time ever, the researchers were able to convert human embryonic stem cells into dopamine producing neurons, which behaved like native dopamine cells lost in the disease.

The study was led by Malin Parmar, associate professor in Lund's Department of Medicine, and conducted at both Lund University and at MIRCen in Paris as part of the EU networks NeuroStemCell and NeuroStemcellRepair.

According to Medical News Today, the researchers produced rat models of Parkinson's disease by destroying the dopamine cells in one part of the rat's brain, and then they transplanted the new dopamine producing stem cell neurons. These next generation dopamine neurons were found to survive long term, restore the lost dopamine, and form long distance connections to the correct parts of the brain when transplanted into rats. Most excitingly, these transplanted stem cells reversed the damage from the disease.

As the new dopamine neurons have the same properties and functions of native cells lost in Parkinson's disease and can be produced in unlimited quantities from stem cell lines, this treatment shows promise in moving into clinical applications as stem cell transplants for Parkinsons.

"This study shows that we can now produce fully functioning dopamine neurons from stem cells. These cells have the same ability as the brains normal dopamine cells to not only reach but also to connect to their target area over longer distances. This has been our goal for some time, and the next step is to produce the same cells under the necessary regulations for human use. Our hope is that they are ready for clinical studies in about three years", says Malin Parmar.

Human embryonic stem cells (ESC) are powerful treatment options due to their ability to change into any cell type in the body. However, it is difficult to get them to change into the desired cell types, and research efforts are also hampered due to the ethical concerns associated with embryonic stem cells.

The study is published in the journal,Cell Stem Cell, titled Human ESC-Derived Dopamine Neurons Show Similar Preclinical Efficacy and Potency to Fetal Neurons when Grafted in a Rat Model of Parkinsons Disease.

See original here:
Researchers Discover Breakthrough Stem Cell Treatment For Parkinson's Disease

Ilfords Fathima Hilmy finds possible stem cell match in Brazil

By Stem Cell Doctors

12:44 11 November 2014

Harry Kemble

Fathima Hilmy, of High Road, Ilford.

Archant

A 25-year-old teaching assistant may have had her international appeal for a stem cell donor answered.

Email this article to a friend

To send a link to this page you must be logged in.

Sri Lankan Fathima Hilmy, of High Road, Ilford - known as Fathima Nusla by her community - has been told by doctors she has an 80 per cent chance of a successful match after a potential donor was found in Brazil.

The unnamed donor will now be medically tested to see if they can undergo the intensive and challenging procedure.

Fathima, 25, has been in and out of hospital after being originally diagnosed with acute myeloid leukaemia in 2012.

Go here to read the rest:
Ilfords Fathima Hilmy finds possible stem cell match in Brazil

→←